Microvascular Complications and Foot Care

3.2.11.0 Sec­tion 11

To align with the ADA-‍EASD con­sen­sus re­port, a rec­om­men­da­tion was added for peo­ple with type 2 di­a­betes and chron­ic kid­ney dis­ease to con­sid­er agents with proven benefit with re­gard to renal out­comes.

The rec­om­men­da­tion on the use of telemedicine in reti­nal screen­ing was modified to ac­knowl­edge the util­i­ty of this ap­proach, so long as ap­pro­pri­ate re­fer­rals are made for a com­pre­hen­sive eye ex­am­i­na­tion.

Gabapentin was added to the list of agents to be con­sid­ered for the treat­ment of neu­ro­path­ic pain in peo­ple with di­a­betes based on data on efficacy and the po­ten­tial for cost sav­ings.

The gas­tro­pare­sis sec­tion in­cludes a dis­cus­sion of a few ad­di­tional treat­ment modal­i­ties.

The rec­om­men­da­tion for pa­tients with di­a­betes to have their feet in­spect­ed at every visit was modified to only in­clude those at high risk for ul­cer­a­tion. An­nu­al ex­am­i­na­tions re­main rec­om­mend­ed for ev­ery­one.